New Product for Kids or Adults
Applications For Health Improvement
- Promotes oral health in the mouth
- Supports the natural immune defenses of the ears, nose/nasopharynx, and throat
- Supports healthy immune function
- Naturally promotes fresh breath
30 Chewable Tablets
Our Children’s Probiotic are chewable, naturally flavored strawberry tablets, with a probiotic formula that activates in the mouth for support of ear, nose, and throat health and also naturally promotes fresh breath. The mouth is home to a plethora of naturally occurring bacteria. Some of these microorganisms are an important aspect of maintaining good health and serve as a first line of defense. As your child chews, each tablet releases the ENT-12™ strain of Streptococcus salivarius, a beneficial bacterium that normally occurs in a healthy mouth biome. S salivarius adheres to cells in the oral cavity and positively affects the bacterial population and natural immune defenses therein.
Streptococcus salivarius ENT-12™ (ENT-12), found in our Children’s Probiotics was discovered and isolated by renowned microbiologist Professor John Tagg at the University of Otago in New Zealand. ENT-12 is an extremely safe yet powerful strain that has been deposited in culture collections [1-3]. ENT-12 has been shown to adhere to cells of the oral cavity and populate therein [4-7]. Not only does this strain exert its benefits through the typical colonization or “power in numbers” method, but it also produces several bioactive peptides, including salivaricin A and salivaricin B, that support oral health [4, 5, 8, 9].
Ear, Nose/Nasopharynx, and Throat Health: This formula represent a new “bioprotic” approach; that is, using probiotics to enhance health in non-intestinal sites for specific applications . ENT-12 promotes healthy levels of beneficial oral microorganisms, and thereby supports upper respiratory health . Studies suggest that children with naturally occurring S salivarius ENT-12−like strains are better able to maintain healthy mouth and throat microbial populations. Preliminary studies performed in children and adults have shown that supplementation with ENT-12 has a statistically significant impact on throat, tonsil, and middle ear health [4,5].
Fresh Breath: The predominant microbiota on the tongue of subjects with and without bad breath differs . When certain bacteria break down proteins on the tongue volatile sulfur compounds (VSC), which cause bad breath, are released. In a placebo-controlled trial, Burton et al showed that administration of the ENT-12 strain in 13 subjects resulted in a substantial decrease in VSC levels compared to controls . The introduction of ENT-12 helps to balance the microflora of the mouth because it competes with the sulfur-producing bacteria for space while leaving room for more good bacteria to flourish [11-13]. This method of supporting a microbial population that limits the activities of sulfur-producing bacteria gets to the source of bad breath [11,12]. Addressing bad breath at its source can provide longer-lasting results than methods that simply mask odors.
For Best Results: Tablets should be chewed slowly and thoroughly. As a maintenance dose, before your child goes to sleep and after they have finished with their brushing, flossing, and/or rinsing routines, chew one tablet slowly and completely before swallowing. During periods of increased need, chew up to five tablets per day in divided dose for 90 days, or as directed by your healthcare professional.
The tablets do not contain cariogenic sugars or other ingredients that could negatively affect dental health. Tablets are individually sealed in nitrogen-purged aluminum blister packs, which serve as protection from factors proven to compromise the stability of probiotics, such as heat, moisture, and oxygen.
ADULTS can also use this product.
CAUTION: Not recommended for children aged 4 or younger without the direct recommendation and supervision of a healthcare practitioner. This product should be administered by an adult. Pregnant or lactating women should consult their healthcare practitioner prior to use.
- Burton JP, Cowley S, Simon RR, et al. Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: a randomized, placebocontrolled, double-blind study. Food Chem Toxicol. 2011 Sep;49(9):2356-64. [PMID: 21722694]
- Guglielmetti S, Taverniti V, Minuzzo M, et al. Oral bacteria as potential probiotics for the pharyngeal mucosa. Appl Environ Microbiol. 2010 Jun;76(12):3948- 58.[PMID: 20418429]
- Burton JP, Wescombe PA, Moore CJ, et al. Safety assessment of the oral cavity probiotic Streptococcus salivarius K12. Appl Environ Microbiol. 2006 Apr;72(4):3050-53. [PMID: 16598017]
- Di Pierro F, Donato G, Fomia F, et al. Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med. 2012;5:991-97. [PMID: 23233809]
- Di Pierro F, Adami T, Rapacioli G, et al. Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults. Expert Opin Biol Ther. 2013 Mar;13(3):339-43. [PMID: 23286823]
- Horz HP, Meinelt A, Houben B, et al. Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by realtime quantitative polymerase chain reaction. Oral Microbiol Immunol. 2007 Apr;22(2):126-30. [PMID: 17311636]
- Streptococcus salivarius K12 colonisation - dose response. BLIS Technologies Ltd. June 9, 2009. Data on file.
- Power DA, Burton JP, Chilcott CN, et al. Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. Eur J Clin Microbiol Infect Dis. 2008 Dec;27(12):1261-63. [PMID: 18560907]
- Tagg JR. Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius. Indian J Med Res. 2004 May;119 Suppl:13-16. [PMID: 15232154]
- Kazor CE, Mitchell PM, Lee AM, et al. Diversity of bacterial populations on the tongue dorsa of patients with halitosis and healthy patients. J Clin Microbiol. 2003 Feb;41(2):558-63. [PMID: 12574246]
- Burton JP, Chilcott CN, Moore CJ, et al. A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J Appl Microbiol. 2006 Apr;100(4):754-64. [PMID: 16553730]
- Burton JP, Chilcott CN, Tagg JR. The rationale and potential for the reduction of oral malodour using Streptococcus salivarius probiotics. Oral Dis. 2005;11 Suppl 1:29-31. [PMID: 15752094]
- Masdea L, Kulik EM, Hauser-Gerspach I, et al. Antimicrobial activity of Streptococcus salivarius K12 on bacteria involved in oral malodour. Arch Oral Biol. 2012 Aug;57(8):1041-47. [PMID: 22405584]